InvestorsHub Logo
Followers 138
Posts 22888
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Sunday, 05/08/2022 4:01:59 PM

Sunday, May 08, 2022 4:01:59 PM

Post# of 660
Can't be in 2 places at one time. Especially if one of theos3e places is possibly discussions with FDA.

The analyst wrote in a note that they received an update from Axsome management regarding today’s pressure. The update confirmed the company is unable to attend the conference in-person due to a scheduling conflict.

Purohit pointed to Axsome management guidance of potential action by the Food and Drug Administration on the New Drug Application for depression treatment AXS-05, explaining that “given the high degree of investor focus & perceived uncertainty regarding this catalyst, some investors may see the cancellation as reason for caution regarding a potential AXS-05 update. “

“However, mgt noted in their update that they will be conducting investor meetings virtually and noted that the company is not aware of additional negative developments,” he wrote.

“We continue to see the expected upcoming FDA action on AXS-05 as a significant catalyst for AXSM, and anticipate + 40% -60% upside upon news of an approval or entry into labeling discussions and 50% + pressure from the announcement of a CRL and / or additional deficiencies, “the analyst added.


https://investorshub.advfn.com/secure/post_new.aspx?board_id=31920

Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXSM News